Literature DB >> 19374843

Biological effects of hexitol and altritol-modified siRNAs targeting B-Raf.

Michael Fisher1, Mikhail Abramov, Arthur Van Aerschot, Jef Rozenski, Vidula Dixit, Rudy L Juliano, Piet Herdewijn.   

Abstract

Increasing the effectiveness of siRNAs through chemical modification is an important task. Here we describe altritol and hexitol modified oligonucleotides targeting the B-Raf oncogene that is critical for the growth and survival of melanoma cells. Using assays for apoptosis, DNA synthesis, colony formation and B-Raf protein and message levels, we demonstrate that certain hexitol modifications can improve the effectiveness of B-Raf siRNAs and also increase duration of action. Altritol modified siRNAs were similar to or slightly less effective than unmodified B-Raf siRNA. Modifications at the 3' or 5' end of the sense strand, at the 3' end of the antisense strand, or within either strand were well tolerated. The basis for the increased effectiveness of the hexitol-modified siRNAs is not fully understood but may be partly due to increased stability to nucleases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19374843      PMCID: PMC2673019          DOI: 10.1016/j.ejphar.2009.01.030

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  19 in total

Review 1.  Flow cytometric methods for detection and quantification of apoptosis.

Authors:  David P Steensma; Michael Timm; Thomas E Witzig
Journal:  Methods Mol Med       Date:  2003

2.  Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells.

Authors:  Frank Czauderna; Melanie Fechtner; Sibylle Dames; Hüseyin Aygün; Anke Klippel; Gijsbertus J Pronk; Klaus Giese; Jörg Kaufmann
Journal:  Nucleic Acids Res       Date:  2003-06-01       Impact factor: 16.971

3.  Rational siRNA design for RNA interference.

Authors:  Angela Reynolds; Devin Leake; Queta Boese; Stephen Scaringe; William S Marshall; Anastasia Khvorova
Journal:  Nat Biotechnol       Date:  2004-02-01       Impact factor: 54.908

Review 4.  RNA interference and chemically modified small interfering RNAs.

Authors:  Muthiah Manoharan
Journal:  Curr Opin Chem Biol       Date:  2004-12       Impact factor: 8.822

Review 5.  Control of translation and mRNA degradation by miRNAs and siRNAs.

Authors:  Marco Antonio Valencia-Sanchez; Jidong Liu; Gregory J Hannon; Roy Parker
Journal:  Genes Dev       Date:  2006-03-01       Impact factor: 11.361

6.  3' UTR seed matches, but not overall identity, are associated with RNAi off-targets.

Authors:  Amanda Birmingham; Emily M Anderson; Angela Reynolds; Diane Ilsley-Tyree; Devin Leake; Yuriy Fedorov; Scott Baskerville; Elena Maksimova; Kathryn Robinson; Jon Karpilow; William S Marshall; Anastasia Khvorova
Journal:  Nat Methods       Date:  2006-03       Impact factor: 28.547

Review 7.  Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.

Authors:  Jared A Gollob; Scott Wilhelm; Chris Carter; Susan L Kelley
Journal:  Semin Oncol       Date:  2006-08       Impact factor: 4.929

8.  B-RAF is a therapeutic target in melanoma.

Authors:  Maria Karasarides; Antonio Chiloeches; Robert Hayward; Dan Niculescu-Duvaz; Ian Scanlon; Frank Friedlos; Lesley Ogilvie; Douglas Hedley; Jan Martin; Christopher J Marshall; Caroline J Springer; Richard Marais
Journal:  Oncogene       Date:  2004-08-19       Impact factor: 9.867

9.  Structural characterization and biological evaluation of small interfering RNAs containing cyclohexenyl nucleosides.

Authors:  Koen Nauwelaerts; Michael Fisher; Matheus Froeyen; Eveline Lescrinier; Arthur Van Aerschot; Dong Xu; Robert DeLong; Hyumin Kang; Rudolph L Juliano; Piet Herdewijn
Journal:  J Am Chem Soc       Date:  2007-07-06       Impact factor: 15.419

10.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

View more
  13 in total

Review 1.  Strategies, design, and chemistry in siRNA delivery systems.

Authors:  Yizhou Dong; Daniel J Siegwart; Daniel G Anderson
Journal:  Adv Drug Deliv Rev       Date:  2019-05-15       Impact factor: 15.470

2.  Crystallization and preliminary X-ray study of the D-altritol oligonucleotide GTGTACAC.

Authors:  Margriet Ovaere; Arthur Van Aerschot; Mikhail Abramov; Piet Herdewijn; Luc Van Meervelt
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2010-03-31

3.  The application of RNAi-based treatments for inflammatory bowel disease.

Authors:  Morten Tobias Jarlstad Olesen; Borja Ballarín-González; Kenneth Alan Howard
Journal:  Drug Deliv Transl Res       Date:  2014-02       Impact factor: 4.617

4.  Hybridization potential of oligonucleotides comprising 3'-O-methylated altritol nucleosides.

Authors:  G Chatelain; G Schepers; J Rozenski; Arthur Van Aerschot
Journal:  Mol Divers       Date:  2012-10-09       Impact factor: 2.943

5.  7-Substituted 8-aza-7-deazaadenosines for modification of the siRNA major groove.

Authors:  José M Ibarra-Soza; Alexi A Morris; Prasanna Jayalath; Hayden Peacock; Wayne E Conrad; Michael B Donald; Mark J Kurth; Peter A Beal
Journal:  Org Biomol Chem       Date:  2012-07-05       Impact factor: 3.876

6.  Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering.

Authors:  Jesper B Bramsen; Jørgen Kjems
Journal:  Front Genet       Date:  2012-08-20       Impact factor: 4.599

7.  How does hydroxyl introduction influence the double helical structure: the stabilization of an altritol nucleic acid:ribonucleic acid duplex.

Authors:  Margriet Ovaere; Jiri Sponer; Judit E Sponer; Piet Herdewijn; Luc Van Meervelt
Journal:  Nucleic Acids Res       Date:  2012-05-25       Impact factor: 16.971

8.  In vivo screening of modified siRNAs for non-specific antiviral effect in a small fish model: number and localization in the strands are important.

Authors:  Brian Dall Schyth; Jesper Bertram Bramsen; Malgorzata Maria Pakula; Sekar Larashati; Jørgen Kjems; Jesper Wengel; Niels Lorenzen
Journal:  Nucleic Acids Res       Date:  2012-01-28       Impact factor: 16.971

9.  RNA as a stable polymer to build controllable and defined nanostructures for material and biomedical applications.

Authors:  Hui Li; Taek Lee; Thomas Dziubla; Fengmei Pi; Sijin Guo; Jing Xu; Chan Li; Farzin Haque; Xing-Jie Liang; Peixuan Guo
Journal:  Nano Today       Date:  2015-10-01       Impact factor: 20.722

10.  Chimeric siRNAs with chemically modified pentofuranose and hexopyranose nucleotides: altritol-nucleotide (ANA) containing GalNAc-siRNA conjugates: in vitro and in vivo RNAi activity and resistance to 5'-exonuclease.

Authors:  Pawan Kumar; Rohan Degaonkar; Dale C Guenther; Mikhail Abramov; Guy Schepers; Marie Capobianco; Yongfeng Jiang; Joel Harp; Charalambos Kaittanis; Maja M Janas; Adam Castoreno; Ivan Zlatev; Mark K Schlegel; Piet Herdewijn; Martin Egli; Muthiah Manoharan
Journal:  Nucleic Acids Res       Date:  2020-05-07       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.